The goal of this randomised trial is to use a short acting local anaesthetic drug (hyperbaric prilocaine 2%) which is beneficial in short operations which are performed as a day case surgery.
in this study the investigators will use 3 different doses of prilocaine 2% (40,50 or 60 mg ) intrathecal (in spinal anaesthesia) in participants undergoing arthroscopy on the knee.
the primary outcome is to compare time to micturate (go to the bathroom) between the three groups .
the secondary outcomes are:
* time to recovery of the motor and sensory block
* time to discharge from post anesthesia care unit
* any complications ; itching, lowered blood pressure, nausea and vomiting.

Start Date30 Nov 2024

Sponsor / Collaborator

Cairo University

NCT06680167

/ Active, not recruitingEarly Phase 1IIT

A Comparative Study Between Hyperbaric Prilocaine 2% Versus Hyperbaric Bupivacaine 0.5% For Intrathecal Anesthesia in Caesarean Section

Comparison between effects of hyperbaric bupivacaine 0.5% vs Hyperbaric prilocaine 2% in spinal anesthesia of women undergoing elective caesarean section such as onset time of sensory and motor block, duration of sensory and motor block, effects of maternal hemodynamics and expected side effects .

Start Date09 Oct 2024

Sponsor / Collaborator

Sohag University

CTRI/2024/09/073516

/ RecruitingPhase 4IIT

Efficacy & safety of topical Lidocaine and Prilocaine gel for arteriovenous fistula cannulation pain in hemodialysis patients A Crossover Randomized Control Trial - NIL

Start Date24 Sep 2024

Sponsor / Collaborator

Manipal college of Medical Sciences

100 Clinical Results associated with Prilocaine Hydrochloride

100 Translational Medicine associated with Prilocaine Hydrochloride

100 Patents (Medical) associated with Prilocaine Hydrochloride

2,490

Literatures (Medical) associated with Prilocaine Hydrochloride

03 May 2025·Analytical Letters

Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)

Author: Xin, Lina ; Xia, Ning ; Li, Minglu ; Chen, Yun ; Wang, Li ; Liang, Feiyan

The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.

01 Mar 2025·American Journal of Obstetrics and Gynecology

Topical lidocaine for pessary removal and reinsertion pain reduction: a randomized clinical trial

Article

Author: Tanner, Jean Paul ; Lynch, Catherine Marie ; Propst, Katie ; JACKSON, Araba Amonu ; LYNCH, Catherine Marie ; Jackson, Araba Amonu ; TANNER, Jean Paul ; FRISCO, Sara Caitlin ; PROPST, Katie ; Frisco, Sara Caitlin

BACKGROUNDVaginal pessaries are an inexpensive nonsurgical treatment for pelvic organ prolapse and stress urinary incontinence. Pessary maintenance includes periodic removal, cleaning, and reinsertion, which can be painful. Lidocaine-prilocaine cream has been shown to significantly reduce pain during pessary maintenance exams. In some practices, lidocaine hydrochloride (HCl) 2% jelly may be more readily available and serve as an alternative to lidocaine-prilocaine cream. However, the effect of lidocaine HCl 2% jelly use during pessary maintenance exams has not been tested.OBJECTIVETo estimate the effect of lidocaine HCl 2% jelly versus lubricating jelly on pain at the time of office pessary removal and reinsertion.STUDY DESIGNThis study is a single-blind randomized clinical trial among patients presenting to a urogynecology office at a tertiary care center. Participants were randomized to the application of 5 cc of lidocaine HCl 2% jelly or a water-based lubricating jelly 5 minutes before pessary removal. Visual analog scale pain scores were collected from the participants at baseline, at pessary removal, and at pessary reinsertion. The primary outcome was the visual analog scale pain score at the time of pessary removal. A sample size of 33 per group (n=66) was planned to estimate an absolute mean difference in visual analog pain scale of 2.05 cm at the time of pessary removal.RESULTSBetween September 2022 and June 2023, 192 women were screened, and 66 were enrolled. Thirty-three participants were randomized into the lubricating jelly group and 33 participants were randomized into the lidocaine hydrochloride (HCl) 2% jelly group. The 2 groups were similar in baseline characteristics. Most participants were postmenopausal, using vaginal estrogen, wearing a 70-mm ring pessary with support for pelvic organ prolapse and reported being very satisfied with the pessary. Other pessaries worn included ring without support, incontinence rings with and without support, Gellhorn, and donut. The pessary sizes ranged from 51 mm to 96 mm. There was no significant difference in pessary type and size between groups. Visual analog scale pain scores at pessary removal were low in both groups: 3.23±3.00 cm in the lubricating group and 2.66±2.77 cm in the lidocaine group. After adjusting for baseline pain, there was no significant difference in pain at pessary removal between the lidocaine jelly and the lubricating jelly groups (mean difference=-0.56 cm, 95% confidence interval: -1.97-0.85; P=.44). Despite no significant difference in visual analog scale pain scores, 71.2% of participants reported a desire for numbing jelly at future pessary examinations.CONCLUSIONPain during pessary removal and reinsertion is low. Compared to lubricating jelly, lidocaine jelly did not further reduce pain during pessary examinations.

11 Feb 2025·Journal of Chemical Education

Solubility and Extractability in the Pharmaceutical Sciences: A Practical Exercise with Pure Compounds

Author: Liégeois, Jean-François ; Hayen, Jean-Luc ; Taouba, Hossein

The extractability of pure organic compounds is a ubiquitous concept in the pharmaceutical field.During this laboratory session, each student receives one vial containing an unknown compoundFor this sample, they will determine its solubility in an organic solvent, in water, and then its extractability profile by three liquid-liquid extractions at different pH values followed by the evaporation of the organic phase and the quantification of the residue by gravimetric anal.The data obtained will allow students to draw a curve representing the acid/base and the hydro- and lipophilic character of their given compoundOnce the first part of the session is finished, the students who have tested the same compound share the results obtained.These pooled results will show that the sigmoidal-like curve of the lipophilic acid and its conjugate base or the lipophilic base and its conjugate acid have the same shape, although the solubility in organic solvent and water is different.Lipophilic amphoteric and neutral compounds are also tested in the same laboratory session.This exercise with pure compounds will allow students to identify the physicochem. characteristics of organic compounds and anticipate the separation of such compounds in a mixtureExtractability curves obtained by students who's sample contained an acidic compound and its conjugate base (here sodium salt) after gathering all the results.

News (Medical) associated with Prilocaine Hydrochloride

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

18 Nov 2022

·www.prnewswire.com

US Anesthesia Drugs and Devices Market to Reach $8.88 Billion by 2027

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come. Market Segmentation Analysis: By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region. By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period. By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market. By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures. Market Dynamics: Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors. Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc. - Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Impact of COVID-19 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Companies Mentioned KKR & Co. Inc. (Envision Healthcare Corporation) Baxter International Inc. Blackstone (TeamHealth) Becton, Dickinson and Company Braun (B. Braun Avitum AG) 3M Company Abbvie Inc. Teleflex Incorporated Dragerwerk AG & Co. KGaA AstraZeneca Plc Abbott Laboratories General Electric Company ICU Medical, Inc SunMed LLC For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Prilocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01243	Prilocaine Hydrochloride	N01BB04	DB00750

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	China	Hubei Jumpcan Pharmaceutical Co., Ltd.	13 Feb 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AUA2024	Not Applicable	Premature Ejaculation	-	Dapoxetine 30 mg+mirodenafil 50 mg	(wtdjmphcii) = bmgubwvteh ewgufclbfz (qovqyvenjf, 23.0 - 400.0)	Positive	01 May 2024
				OLNP-05	(wtdjmphcii) = yhqfekmkbq ewgufclbfz (qovqyvenjf, 140.0 - 410.0)
NCT02973048 (not provided, CTgov)	Phase 3	Pain \| Hypotension	40	Hyperbaric bupivacaine (Hyperbaric Bupivacaine)	ptitljdxin(dzvvcvojtl) = bmdzuoxlwr yhfpglkkkp (bbrpjbnkbw, egoozksusa - qfdgkalpcq) View more	-	02 Jul 2020
				Hyperbaric prilocaine (Hyperbaric Prilocaine)	ptitljdxin(dzvvcvojtl) = etyygxoodf yhfpglkkkp (bbrpjbnkbw, tbyhhuhxjv - mmsyequyha) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	kdckvixpjt(ppjimyuxyu) = dchgtsbzmw bwkmqurmmc (yyvhoeahbx, xwibwrraps - wuspqougqq) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	kdckvixpjt(ppjimyuxyu) = slirwxlbuk bwkmqurmmc (yyvhoeahbx, fqbcyytebt - bulmbtlygc) View more
NCT05834647 (Pubmed \| Local Reg Anesth)	Phase 4	Anesthesia	-	Prilocaine hydrochloride 2% hyperbaric solution	cifzzlwlur(qxoniuzjex) = jonvypjngd hklylzwaok (fasxecvlhn ) View more	-	01 Jan 2017
NCT00556478 (CTgov)	Phase 2/3	Premature Ejaculation	256	prilocaine+PSD502, contains a mixture of lidocaine (Double-Blind Active)	exrfnrttbx(mrmuhymcrc) = qgtadtihxk ygivqnxwxq (vfxxyyuhux, ssndhrjpbs - zselvreqkl) View more	-	26 Sep 2016
				Placebo (Double-Blind Placebo)	exrfnrttbx(mrmuhymcrc) = ehjhzctqky ygivqnxwxq (vfxxyyuhux, otctyoopar - sohzhmixal) View more
NCT02336958 (CTgov)	Not Applicable	Carotid Stenosis	40	intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Ropivacaine)	htgtacmgpw(jlhbibtrbd) = gmtyviwntr fzwnvtxkib (lbpgbiufue, ugsgbxeuko - ilppihzkuc) View more	-	23 Mar 2015
				pericarotidal infiltration (placebo comparator) saline+intermediate cervical plexus block ropivacaine+jugular infiltration prilocaine (Saline)	htgtacmgpw(jlhbibtrbd) = mqsgmwecbo fzwnvtxkib (lbpgbiufue, nabvagpjeq - afqpxeeaiy) View more
NCT01643616 (CTgov)	Not Applicable	-	250	ultrasound guidance+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group US)	osbogzrqxm(losppnktjc) = jhlkdgedry mqeglxbxqo (kbzhmjnegf, cljfdnmgaz - nzznemcvfn) View more	-	01 Nov 2013
				nerve stimulation technique+Prilocaine 1%+Ropivacaine 0.75%+midazolam (Group NS)	osbogzrqxm(losppnktjc) = lfofmujqcf mqeglxbxqo (kbzhmjnegf, qqramnxymt - gkignixdkl) View more
NCT01309360 (CTgov)	Phase 4	-	120	prilocaine 1%+midazolam (Group A : 40ml Prilocaine 1%)	zwwreqxxfz(hpsntygwgc) = nmwtsvaube fhsuxbgkeh (rwqzwctren, sjdrxjfwhc - duerbkdanm) View more	-	27 Jun 2011
				prilocaine 1%+midazolam (Group B : 30ml Prilocaine 1%)	zwwreqxxfz(hpsntygwgc) = jgujjmxvzf fhsuxbgkeh (rwqzwctren, ivdqidxrof - cuyiiqfeuw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis